Indefinite Delivery Contract SPE2DB24D1104

This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp's Corporate Office Division. The single-award IDC, valued up to $999,999,999.00 through December 31, 2025, serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Under this contract, Amerisourcebergen provides prescription medications, over-the-counter drugs, and critical medical supplies such as syringes, vials, and test kits. The IDC enables the DLA to efficiently procure essential medical commodities for military treatment programs and facilities globally, supporting the agency's mission. Additionally, Amerisourcebergen holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.

The contract does not have any set-aside designations, indicating the awards were made on a full and open competition basis. The task orders under this IDC cover a diverse range of pharmaceutical products, including specialty, brand name, generic, and over-the-counter medications, as well as medical devices and supplies. Recent orders have included items such as insulin pumps, Humira syringes, Symbicort inhalers, Prevnar 20 vaccines, and various prescription drugs for conditions like diabetes, hypertension, and others. The delivery orders are awarded with firm fixed-price pricing and have performance periods generally ending in April or May 2024, with a few extending into the following year.